These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 22577589)

  • 41. Innate immunity in systemic sclerosis pathogenesis.
    O'Reilly S
    Clin Sci (Lond); 2014 Mar; 126(5):329-37. PubMed ID: 24219159
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interactions of oral pathogens with toll-like receptors: possible role in atherosclerosis.
    Hajishengallis G; Sharma A; Russell MW; Genco RJ
    Ann Periodontol; 2002 Dec; 7(1):72-8. PubMed ID: 16013219
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulation of innate immune responses by Toll-like receptors.
    Takeda K; Akira S
    Jpn J Infect Dis; 2001 Dec; 54(6):209-19. PubMed ID: 11862002
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells.
    Tartey S; Takeuchi O
    Int Rev Immunol; 2017 Mar; 36(2):57-73. PubMed ID: 28060562
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Toll-like receptors in kidney disease.
    Smith KD
    Curr Opin Nephrol Hypertens; 2009 May; 18(3):189-96. PubMed ID: 19352178
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Toll-like receptors: Triggers of regulated cell death and promising targets for cancer therapy.
    Yang Y; Feng R; Wang YZ; Sun HW; Zou QM; Li HB
    Immunol Lett; 2020 Jul; 223():1-9. PubMed ID: 32311408
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Application potential of toll-like receptors in cancer immunotherapy: Systematic review.
    Shi M; Chen X; Ye K; Yao Y; Li Y
    Medicine (Baltimore); 2016 Jun; 95(25):e3951. PubMed ID: 27336891
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Toll-like receptors and diabetes: a therapeutic perspective.
    Dasu MR; Ramirez S; Isseroff RR
    Clin Sci (Lond); 2012 Mar; 122(5):203-14. PubMed ID: 22070434
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The critical role of Toll-like receptor signaling pathways in the induction and progression of autoimmune diseases.
    Li M; Zhou Y; Feng G; Su SB
    Curr Mol Med; 2009 Apr; 9(3):365-74. PubMed ID: 19355917
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies.
    Martinsen JT; Gunst JD; Højen JF; Tolstrup M; Søgaard OS
    Front Immunol; 2020; 11():1112. PubMed ID: 32595636
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multi-Drug Resistance and Breast Cancer Progression via Toll-Like Receptors (TLRs) Signaling.
    Pallathadka H; Khaleel AQ; Zwamel AH; Malathi H; Sharma S; Rizaev JA; Mustafa YF; Pramanik A; Shuhata Alubiady MH; Jawad MA
    Cell Biochem Biophys; 2024 Dec; 82(4):3015-3030. PubMed ID: 39110298
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TLRs are important inflammatory factors in atherosclerosis and may be a therapeutic target.
    Liu Y; Yu H; Zhang Y; Zhao Y
    Med Hypotheses; 2008; 70(2):314-6. PubMed ID: 17689203
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Innate immune receptor Toll-like receptor 4 signalling in neuropsychiatric diseases.
    García Bueno B; Caso JR; Madrigal JL; Leza JC
    Neurosci Biobehav Rev; 2016 May; 64():134-47. PubMed ID: 26905767
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Toll-like receptors and viruses: induction of innate antiviral immune responses.
    Xagorari A; Chlichlia K
    Open Microbiol J; 2008; 2():49-59. PubMed ID: 19088911
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Toll-like receptor modulation: a novel therapeutic strategy in cardiovascular disease?
    Katsargyris A; Klonaris C; Bastounis E; Theocharis S
    Expert Opin Ther Targets; 2008 Nov; 12(11):1329-46. PubMed ID: 18851691
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Toll gates: An emerging therapeutic target.
    Maheaswari R; Sivasankar K; Subbarayan S
    J Indian Soc Periodontol; 2014; 18(6):686-92. PubMed ID: 25624622
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system.
    Netea MG; van der Graaf C; Van der Meer JW; Kullberg BJ
    J Leukoc Biol; 2004 May; 75(5):749-55. PubMed ID: 15075354
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Understanding and modulating the Toll like Receptors (TLRs) and NOD like Receptors (NLRs) cross talk in type 2 diabetes.
    Prajapati B; Jena PK; Rajput P; Purandhar K; Seshadri S
    Curr Diabetes Rev; 2014 May; 10(3):190-200. PubMed ID: 24828062
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Toll-like receptor expression and function in type I bipolar disorder.
    Wieck A; Grassi-Oliveira R; do Prado CH; Viola TW; Petersen LE; Porto B; Teixeira AL; Bauer ME
    Brain Behav Immun; 2016 May; 54():110-121. PubMed ID: 26795430
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Toll-like receptors: promising therapeutic targets for inflammatory diseases.
    Achek A; Yesudhas D; Choi S
    Arch Pharm Res; 2016 Aug; 39(8):1032-49. PubMed ID: 27515048
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.